|Articles|October 31, 2012

SARcode reports phase III results for lifitegrast

SARcode Bioscience Inc. announced the topline results from OPUS-1, a pivotal phase III study of lifitegrast ophthalmic solution 5.0% for the treatment of dry eye disease.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.


Latest CME